These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16110007)

  • 1. Gefitinib in colorectal cancer: if wishes were horses.
    Blanke CD
    J Clin Oncol; 2005 Aug; 23(24):5446-9. PubMed ID: 16110007
    [No Abstract]   [Full Text] [Related]  

  • 2. First-line erlotinib inferior to chemo in advanced lung cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):930-1. PubMed ID: 23176004
    [No Abstract]   [Full Text] [Related]  

  • 3. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 4. Erlotinib in lung cancer.
    Nabhan C; Bitran JD
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16236747
    [No Abstract]   [Full Text] [Related]  

  • 5. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical solutions to epidermal growth factor receptor tyrosine kinase inhibitor dose modifications in resource-constrained settings: Thinking outside the (packaging) box.
    Singh N; Prasad KT
    Indian J Cancer; 2017; 54(1):186-187. PubMed ID: 29199687
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimising therapy for EGFR-addicted NSCLC: just the start.
    Govindan R; Subramanian J
    Lancet Oncol; 2012 Mar; 13(3):216-7. PubMed ID: 22285167
    [No Abstract]   [Full Text] [Related]  

  • 8. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
    Mitsudomi T
    Lancet Oncol; 2011 Aug; 12(8):710-1. PubMed ID: 21783418
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of gefitinib and erlotinib.
    Levêque D
    Lancet Oncol; 2011 Nov; 12(12):1093. PubMed ID: 22041538
    [No Abstract]   [Full Text] [Related]  

  • 11. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 12. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 14. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Zalcman G; Bergot E
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
    [No Abstract]   [Full Text] [Related]  

  • 15. Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
    Jänne PA
    Am J Respir Crit Care Med; 2008 Oct; 178(8):783-5. PubMed ID: 18832554
    [No Abstract]   [Full Text] [Related]  

  • 16. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
    Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
    Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
    Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
    Lee D
    Clin Lung Cancer; 2005 Sep; 7(2):89-91. PubMed ID: 16179094
    [No Abstract]   [Full Text] [Related]  

  • 19. [Erlotinib in non-small cell lung cancer].
    Takeda M; Okamoto I
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib: phoenix from the flames.
    Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.